{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:25:56Z","timestamp":1787811956422,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["K12AR084231"],"award-info":[{"award-number":["K12AR084231"]}]},{"name":"NIH","award":["P30CA014236"],"award-info":[{"award-number":["P30CA014236"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1245\/s10434-024-15793-w","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T14:02:36Z","timestamp":1720447356000},"page":"7290-7300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Demographics and Clinical Decision Making in Patients with Germline Moderate Penetrance Non-BRCA Mutations in Breast Cancer Related Genes"],"prefix":"10.1245","volume":"31","author":[{"given":"Koumani W.","family":"Ntowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha M.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet C.","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebunoluwa","family":"Olunuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ton","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7411-0558","authenticated-orcid":false,"given":"Jennifer K.","family":"Plichta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"issue":"6","key":"15793_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524\u201341.","journal-title":"CA Cancer J Clin."},{"issue":"5","key":"15793_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu C, Hart SN, Gnanaolivu R, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384(5):440\u201351.","journal-title":"N Engl J Med."},{"issue":"7","key":"15793_CR3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/annonc\/mdv022","volume":"26","author":"S Shiovitz","year":"2015","unstructured":"Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26(7):1291\u20139.","journal-title":"Ann Oncol."},{"issue":"5","key":"15793_CR4","doi-asserted-by":"publisher","first-page":"5741","DOI":"10.1002\/jcp.27464","volume":"234","author":"M Mahdavi","year":"2019","unstructured":"Mahdavi M, Nassiri M, Kooshyar MM, et al. Hereditary breast cancer; genetic penetrance and current status with BRCA. J Cell Physiol. 2019;234(5):5741\u201350.","journal-title":"J Cell Physiol."},{"issue":"23","key":"15793_CR5","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316.","journal-title":"JAMA."},{"issue":"5","key":"15793_CR6","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Gen. 2003;72(5):1117\u201330.","journal-title":"Am J Hum Gen."},{"issue":"11","key":"15793_CR7","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329\u201333.","journal-title":"J Clin Oncol."},{"key":"15793_CR8","doi-asserted-by":"publisher","unstructured":"Ntowe KW, Lee MS, Plichta JK. Clinical genetics in breast cancer. J Surg Oncol. 2024. https:\/\/doi.org\/10.1002\/jso.27630","DOI":"10.1002\/jso.27630"},{"issue":"5","key":"15793_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"Breast Cancer Association Consortium","year":"2021","unstructured":"Breast Cancer Association Consortium. Breast cancer risk genes\u2014association analysis in more than 113,000 women. N Engl J Med. 2021;384(5):428\u201339.","journal-title":"N Engl J Med"},{"issue":"3","key":"15793_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.gde.2010.02.009","volume":"20","author":"A Hollestelle","year":"2010","unstructured":"Hollestelle A, Wasielewski M, Martens JW, Schutte M. Discovering moderate-risk breast cancer susceptibility genes. Curr Opin Genet Dev. 2010;20(3):268\u201376.","journal-title":"Curr Opin Genet Dev."},{"key":"15793_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.breast.2022.06.003","volume":"65","author":"R Graffeo","year":"2022","unstructured":"Graffeo R, Rana HQ, Conforti F, et al. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. The Breast. 2022;65:32\u201340.","journal-title":"The Breast."},{"key":"15793_CR12","unstructured":"Daly MB, Pal T, AlHilli Z, et al. Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, Version 2.2024, NCCN clinical practice guidelines in oncology. National comprehensive cancer network. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf. Published 2024. Updated 09\/23\/2023. Accessed 01\/28\/2024."},{"key":"15793_CR13","unstructured":"Bevers TB, Sardesai S, Ahrendt G, et al. NCCN Guidelines: breast cancer risk reduction (version 1.2024) [Clinical practice guidelines in oncology]. 2024; 1 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast_risk.pdf. Published 10\/31\/2023. Accessed 01\/29\/2024."},{"issue":"12","key":"15793_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/cancers10120524","volume":"10","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos J. BRCA mutations and breast cancer prevention. Cancers. 2018;10(12):524.","journal-title":"Cancers."},{"issue":"6","key":"15793_CR15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","volume":"22","author":"TR Rebbeck","year":"2004","unstructured":"Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2004;22(6):1055\u201362.","journal-title":"J Clin Oncol."},{"issue":"4","key":"15793_CR16","first-page":"CD002748","volume":"4","author":"NE Carbine","year":"2018","unstructured":"Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018;4(4):CD002748.","journal-title":"Cochrane Database Syst Rev."},{"issue":"10","key":"15793_CR17","doi-asserted-by":"publisher","first-page":"e2031","DOI":"10.1002\/mgg3.2031","volume":"10","author":"JG Comeaux","year":"2022","unstructured":"Comeaux JG, Culver JO, Lee JE, et al. Risk-reducing mastectomy decisions among women with mutations in high- and moderate-penetrance breast cancer susceptibility genes. Mol Genet Genomic Med. 2022;10(10):e2031.","journal-title":"Mol Genet Genomic Med."},{"issue":"4","key":"15793_CR18","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1016\/j.clbc.2021.01.008","volume":"21","author":"G Wei","year":"2021","unstructured":"Wei G, Kumar A, Lee MC, Wang X. Influential factors on risk-reduction mastectomy in a high-risk breast cancer population with genetic predispositions. Clin Breast Cancer. 2021;21(4):e427\u201333.","journal-title":"Clin Breast Cancer."},{"key":"15793_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.amjsurg.2023.10.011","volume":"227","author":"SM Record","year":"2024","unstructured":"Record SM, Thomas SM, Ntowe K, Chiba A, Plichta JK. BRCA1\/2 mutation carriers & risk reducing mastectomy: who undergoes surgery and potential benefits. Am J Surg. 2024;227:146\u201352.","journal-title":"Am J Surg."},{"key":"15793_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.breast.2021.08.015","volume":"60","author":"DG Evans","year":"2021","unstructured":"Evans DG, Gandhi A, Wisely J, et al. Uptake of bilateral-risk-reducing-mastectomy: prospective analysis of 7195 women at high-risk of breast cancer. Breast. 2021;60:45\u201352.","journal-title":"Breast."},{"key":"15793_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.breast.2016.08.016","volume":"30","author":"CMG van Driel","year":"2016","unstructured":"van Driel CMG, Oosterwijk JC, Meijers-Heijboer EJ, et al. Psychological factors associated with the intention to choose for risk-reducing mastectomy in family cancer clinic attendees. Breast. 2016;30:66\u201372.","journal-title":"Breast."},{"issue":"3","key":"15793_CR22","doi-asserted-by":"publisher","first-page":"e6311","DOI":"10.1002\/pon.6311","volume":"33","author":"C Torrisi","year":"2024","unstructured":"Torrisi C, Wareg NK, Anbari AB. Decision-making for bilateral risk-reducing mastectomy for an increased lifetime breast cancer risk: a qualitative metasynthesis. Psychooncology. 2024;33(3):e6311.","journal-title":"Psychooncology."},{"issue":"20","key":"15793_CR23","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1200\/JCO.2016.71.6480","volume":"35","author":"AW Kurian","year":"2017","unstructured":"Kurian AW, Li Y, Hamilton AS, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol. 2017;35(20):2232\u20139.","journal-title":"J Clin Oncol."},{"issue":"26","key":"15793_CR24","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1245\/s10434-019-07341-8","volume":"15","author":"JK Plichta","year":"2019","unstructured":"Plichta JK, Sebastian ML, Smith LA, Menendez CS, Johnson AT, Bays SM, Euhus DM, Clifford EJ, Jalali M, Kurtzman SH, Taylor WA. Germline genetic testing: what the breast surgeon needs to know. Ann Surg Oncol. 2019;15(26):2184\u201390.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"15793_CR25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10549-019-05345-2","volume":"177","author":"BAM Heemskerk-Gerritsen","year":"2019","unstructured":"Heemskerk-Gerritsen BAM, Jager A, Koppert LB, et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019;177(3):723\u201333.","journal-title":"Breast Cancer Res Treat."},{"issue":"2","key":"15793_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.2009.22.7991","volume":"28","author":"AW Kurian","year":"2010","unstructured":"Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1\/2 mutation carriers. J Clin Oncol. 2010;28(2):222\u201331.","journal-title":"J Clin Oncol."},{"issue":"1","key":"15793_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10549-017-4476-1","volume":"167","author":"V Giannakeas","year":"2018","unstructured":"Giannakeas V, Narod SA. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy. Breast Cancer Res Treat. 2018;167(1):263\u20137.","journal-title":"Breast Cancer Res Treat."},{"issue":"8","key":"15793_CR28","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/cncr.33357","volume":"127","author":"JO Culver","year":"2021","unstructured":"Culver JO, Ricker CN, Bonner J, et al. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. Cancer. 2021;127(8):1275\u201385.","journal-title":"Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15793-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15793-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15793-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T12:03:26Z","timestamp":1728043406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15793-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["15793"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15793-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"9 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article. J.K.P. was the recipient of research funding from the Color Foundation (2017\u20132018; PI: Plichta) and Earlier.org (2023\u20132024; PI: Plichta). She is a member of Editorial Committee for the American Joint Committee on Cancer (AJCC), the Breast Panel for the AJCC, and the National Comprehensive Cancer Network (NCCN) Breast Cancer Diagnosis and Screening Committee. She is an editorial board member for <i>Ann Surg Oncol<\/i>. S.M.T. is a member of the Evidence-Based Medicine Committee for the AJCC, the Breast Panel for the AJCC, and the Neuroendocrine Tumors Panel for the AJCC. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}